Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
Authors Saito Y, Yokota T, Arai M, Tada Y, Sumitani M
Received 29 June 2018
Accepted for publication 7 November 2018
Published 24 December 2018 Volume 2019:12 Pages 127—138
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Michael Schatman
Yoji Saito,1 Takaaki Yokota,2 Masatsugu Arai,3 Yukio Tada,4 Masahiko Sumitani5
1Department of Anesthesiology, Shimane University Hospital, Shimane, Japan; 2Project Management Department, Shionogi & Co., Ltd, Osaka, Japan; 3Business Development Department, Shionogi & Co., Ltd, Osaka, Japan; 4Biostatistics Center, Shionogi & Co., Ltd, Osaka, Japan; 5Department of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan
Introduction: Naldemedine is a peripherally-acting µ-opioid-receptor antagonist, approved in Japan for opioid-induced constipation (OIC). In two open-label, single-arm, Phase III studies, we evaluated the safety and efficacy of naldemedine in Japanese patients with OIC receiving regular-use opioids (COMPOSE-6) or prolonged-release oxycodone (COMPOSE-7) for chronic noncancer pain.
Methods: Eligible Japanese adults with OIC and chronic noncancer pain received once-daily oral naldemedine 0.2 mg for 48 weeks, irrespective of food intake. Primary end points included measures of treatment-emergent adverse events (TEAEs), pain intensity, and opioid withdrawal. Secondary efficacy end points were evaluated at treatment week 2. Patient Assessment of Constipation Symptoms (PAC-SYM) and Quality of Life (PAC-QOL) scores were evaluated in both 48-week studies.
Results: Of patients enrolled in COMPOSE-6 (N = 43) and COMPOSE-7 (N = 10), TEAEs were reported in 88% (95% CI 74.9–96.1) and 90% (95% CI 55.5–99.7), respectively. The most frequently reported TEAEs, nasopharyngitis and diarrhea, were mostly mild or moderate in severity. Assessments of pain intensity and opioid withdrawal remained stable over the 48-week treatment periods of both studies. The proportion of spontaneous bowel-movement responders at week 2 in COMPOSE-6 was 81.0% (95% CI 65.9–91.4) and 90.0% (95% CI 55.5–99.7) in COMPOSE-7. Significant and sustained improvements in PAC-SYM and PAC-QOL scores were also observed in both studies (all P<0.05).
Conclusion: Side effects that occurred with naldemedine were mostly mild or moderate in severity, and the data suggested that naldemedine can improve bowel function and QOL in Japanese patients with OIC receiving regular-use opioids or prolonged-release oxycodone for chronic noncancer pain.
Keywords: opioids, peripherally-acting μ-opioid-receptor antagonists, patient assessment of constipation QOL, PAC-QOL, patient assessment of constipation symptoms, PAC-SYM, clinical studies, bowel function
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]